Evidence map›Paper›PMID 36925633›Full record

ArticleFrontiers in pharmacology2023

Access to medicines for rare diseases: A European regulatory roadmap for academia.

Noa Rosenberg, Sibren van den Berg, Nina N Stolwijk, Bart A W Jacobs, Hendrika C Post, Anna M G Pasmooij, Saco J de Visser, Carla E M Hollak

Open access · goldFull text read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Noa RosenbergMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
Sibren van den BergMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
Nina N StolwijkMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
Bart A W JacobsMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
Hendrika C PostMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
Anna M G PasmooijDutch Medicines Evaluation Board, Utrecht, Netherlands.
Saco J de VisserMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
Carla E M HollakMedicine for Society, Platform at Amsterdam UMC-University of Amsterdam, Amsterdam, Netherlands.
University of Amsterdam · NLAmsterdam University Medical Centers · NLAmsterdam University of Applied Sciences · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

alternative drug-to-market routesmarketing authorizationorphan drugspatient accessrare diseasesregulatory framework

Identifiers

PMID36925633
PMCPMC10012277
OpenAlexW4323309794

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read13
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.